SAN DIEGO, November 13, 2024--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a ...

Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where ...

U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief ...

The novel oral first-in-class anti-inflammatory agent has demonstrated robust efficacy and high safety margins in preclinical studies, and is the first drug candidate to advance to clinical trials ...

ALTO-100, a first-in-class, oral small molecule believed to work through enhancing neural plasticity, is in development for mood disorders. In October 2024, the Company reported topline results in a ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

Fulcrum's lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of SCD. Fulcrum uses proprietary ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), a clinical-stage ...

New atomic sensor technology enhances MRI quality control by tracking hyperpolarized molecules in real-time, with potential ...

Water and the bad smelling molecule hydrogen sulfide do not seem to have a lot in common at first sight. However, when ...

Supernus Pharmaceuticals is reaping the benefits of its ADHD drug Qelbree, with strong Q3 results and upwardly revised ...